Poor
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely omits the label content (many claims are absent_from_label) and contains a few accurate statements. There are a couple of correct dosage-form claims but also explicit contradictions regarding tablet formulations. Overall alignment is limited, with multiple unsupported claims and some omissions relative to the label.
Category Scores
Accurate Statements
Esomeprazole is a proton pump inhibitor.
12.1
Esomeprazole is used to treat GERD.
1.3
Common formulations include capsules containing 20 mg of esomeprazole.
3
Common formulations include capsules containing 40 mg of esomeprazole.
3
Sometimes oral suspensions for certain age groups.
3
There are potential drug interactions with clopidogrel.
5.7
Unsupported Statements
Nexium is marketed worldwide under the brand name Nexium.
Brand/marketing scope is not described in FDA labeling.
Nexium is marketed as generic esomeprazole in others.
Generic status and market-wide naming are not addressed in labeling.
Esomeprazole is used to treat related conditions.
Label does not list unrelated conditions beyond approved GERD/erosive esophagitis.
Major markets include the United States.
Geographic market availability is not described in labeling.
Major markets include Canada.
Geographic market availability is not described in labeling.
Major markets include most of Europe.
Geographic market availability is not described in labeling.
Major markets include the United Kingdom.
Geographic market availability is not described in labeling.
Major markets include Germany.
Geographic market availability is not described in labeling.
Major markets include France.
Geographic market availability is not described in labeling.
Major markets include Italy.
Geographic market availability is not described in labeling.
Major markets include Spain.
Geographic market availability is not described in labeling.
Major markets include Australia.
Geographic market availability is not described in labeling.
Major markets include New Zealand.
Geographic market availability is not described in labeling.
Major markets include parts of Asia (e.g., Japan, China, India).
Geographic market availability is not described in labeling.
Major markets include many countries in Latin America, the Middle East, and Africa.
Geographic market availability is not described in labeling.
Generic esomeprazole from multiple manufacturers exists after patent expiration.
Generic landscape is not described in labeling.
Nexium requires a prescription in many locations.
Prescribing status is not described in the labeling.
Contradictions
Low
AI Statement
Common formulations include tablets containing 20 mg of esomeprazole.
Label Reference
3
Low
AI Statement
Common formulations include tablets containing 40 mg of esomeprazole.
Label Reference
3
Important Omissions
Pediatric GERD indications (ages 12-17 and 1-11 with suspension) described in label but not reflected in claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label supports GERD indications and clopidogrel interaction; no high-risk safety claims identified in the evaluated statements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overrepresentation of non-label content (brand/generic market details, geographic markets) and incorrect tablet dosage-form claims.
Suggested Improvement
Restrict claims to label-supported content; remove tablet formulation statements unless supported by the label; include pediatric indications present in the label; ensure drug interaction statements reflect exact label language (avoid implying broader claim).